
## Orla Sheils M Sheils

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4547089/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Epigenetic Modifier UHRF1 May Be a Potential Target in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2021, 16, 14-16.	0.5	2
2	Correlation of integrated ERG/PTEN assessment with biochemical recurrence in prostate cancer. Cancer Treatment and Research Communications, 2021, 29, 100451.	0.7	4
3	The Role of Cancer Stem Cells in Drug Resistance in Gastroesophageal Junction Adenocarcinoma. Frontiers in Molecular Biosciences, 2021, 8, 600373.	1.6	3
4	Deep Learning of Histopathological Features for the Prediction of Tumour Molecular Genetics. Diagnostics, 2021, 11, 1406.	1.3	15
5	Circulating Tumour Cell Numbers Correlate with Platelet Count and Circulating Lymphocyte Subsets in Men with Advanced Prostate Cancer: Data from the ExPeCT Clinical Trial (CTRIAL-IE 15-21). Cancers, 2021, 13, 4690.	1.7	11
6	The induction of a mesenchymal phenotype by platelet cloaking of cancer cells is a universal phenomenon. Translational Oncology, 2021, 14, 101229.	1.7	6
7	Developing a health promoting university in Trinity College Dublin—overview and outline process evaluation. Health Promotion International, 2021, , .	0.9	4
8	hsa_circ_0001275 Is One of a Number of circRNAs Dysregulated in Enzalutamide Resistant Prostate Cancer and Confers Enzalutamide Resistance In Vitro. Cancers, 2021, 13, 6383.	1.7	3
9	Prostate cancer-derived holoclones: a novel and effective model for evaluating cancer stemness. Scientific Reports, 2020, 10, 11329.	1.6	10
10	Platelet cloaking of circulating tumour cells in patients with metastatic prostate cancer: Results from ExPeCT, a randomised controlled trial. PLoS ONE, 2020, 15, e0243928.	1.1	13
11	Suppression of Natural Killer cell NKG2D and CD226 anti-tumour cascades by platelet cloaked cancer cells: Implications for the metastatic cascade. PLoS ONE, 2019, 14, e0211538.	1.1	52
12	The effect of a structured exercise intervention on CTCs and platelet cloaking in patients with metastatic prostate cancer Journal of Clinical Oncology, 2019, 37, 243-243.	0.8	2
13	A randomized trial of exercise on quality of life in men with metastatic prostate cancer: The ExPeCT Trial Journal of Clinical Oncology, 2019, 37, 97-97.	0.8	9
14	A novel role for the macrophage galactose-type lectin receptor in mediating von Willebrand factor clearance. Blood, 2018, 131, 911-916.	0.6	54
15	Potentially important miRNAs in enteropathy-associated T-cell lymphoma pathogenesis: A pilot study. Leukemia Research Reports, 2018, 10, 52-54.	0.2	1
16	Integrating biomarkers across omic platforms: an approach to improve stratification of patients with indolent and aggressive prostate cancer. Molecular Oncology, 2018, 12, 1513-1525.	2.1	41
17	Diagnosis, monitoring and prevention of exposure-related non-communicable diseases in the living and working environment: DiMoPEx-project is designed to determine the impacts of environmental exposure on human health. Journal of Occupational Medicine and Toxicology, 2018, 13, 6.	0.9	32
18	Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study. BMC Cancer, 2018, 18, 828.	1.1	19

Orla Sheils M Sheils

#	Article	IF	CITATIONS
19	miR-223 potentially targets SWI/SNF complex protein SMARCD1 in atypical proliferative serous tumor and high-grade ovarian serous carcinoma. Human Pathology, 2017, 70, 98-104.	1.1	14
20	The ExPeCT (Examining Exercise, Prostate Cancer and Circulating Tumour Cells) trial: study protocol for a randomised controlled trial. Trials, 2017, 18, 456.	0.7	6
21	The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review. BMC Cancer, 2017, 17, 697.	1.1	94
22	Response to letter: limitations of human papillomavirus <scp>DNA</scp> testing in measuring previous exposure and vaccine protection. HIV Medicine, 2016, 17, 557-558.	1.0	0
23	HPV vaccine acceptability in HIV-infected and HIV negative men who have sex with men (MSM) in Ireland. Human Vaccines and Immunotherapeutics, 2016, 12, 1536-1541.	1.4	18
24	N-linked glycans within the A2 domain of von Willebrand factor modulate macrophage-mediated clearance. Blood, 2016, 128, 1959-1968.	0.6	31
25	Altered expression of mir-222 and mir-25 influences diverse gene expression changes in transformed normal and anaplastic thyroid cells, and impacts on MEK and TRAIL protein expression. International Journal of Molecular Medicine, 2016, 38, 433-445.	1.8	11
26	Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines. Cancer Biology and Therapy, 2016, 17, 526-542.	1.5	9
27	Interleukin-15 is associated with disease severity in viral bronchiolitis. European Respiratory Journal, 2016, 47, 212-222.	3.1	19
28	Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion. BMC Cancer, 2015, 15, 627.	1.1	55
29	An Association between MicroRNA-21 Expression and Vitamin D Deficiency in Coronary Artery Disease. MicroRNA (Shariqah, United Arab Emirates), 2015, 4, 57-63.	0.6	24
30	Ligation of TLR7 on CD19 <sup>+</sup> CD1d <sup>hi</sup> BÂcells suppresses allergic lung inflammation via regulatory T cells. European Journal of Immunology, 2015, 45, 1842-1854.	1.6	32
31	Rapid and fully automated bacterial pathogen detection on a centrifugal-microfluidic LabDisk using highly sensitive nested PCR with integrated sample preparation. Lab on A Chip, 2015, 15, 3749-3759.	3.1	121
32	Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium. BMC Cancer, 2015, 15, 26.	1.1	49
33	Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer. BMC Cancer, 2015, 15, 547.	1.1	37
34	Human papillomavirus DNA and mRNA prevalence and association with cervical cytological abnormalities in the Irish HIV population. International Journal of STD and AIDS, 2015, 26, 789-795.	0.5	2
35	Enhanced regulation of cell cycle and suppression of osteoblast differentiation molecular signatures by prostate cancer stem-like holoclones. Journal of Clinical Pathology, 2015, 68, 692-702.	1.0	5

Noninvasive Early Biomarkers in Ovarian Cancer. , 2015, , 303-336.

#	Article	IF	CITATIONS
37	The MyD88+ Phenotype Is an Adverse Prognostic Factor in Epithelial Ovarian Cancer. PLoS ONE, 2014, 9, e100816.	1.1	36
38	Prevalence of human papillomavirus in men who have sex with men in the era of an effective vaccine; a call to act. HIV Medicine, 2014, 15, 499-504.	1.0	21
39	Human Papillomavirus (HPV) and the Usefulness of the HPV Vaccine for Men Who Have Sex With Men. Journal of Infectious Diseases, 2014, 210, 1679-1679.	1.9	7
40	An integrated analysis of the SOX2 microRNA response program in human pluripotent and nullipotent stem cell lines. BMC Genomics, 2014, 15, 711.	1.2	19
41	Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening. International Journal of Molecular Sciences, 2013, 14, 2085-2103.	1.8	23
42	Activated Eosinophils in Association with Enteric Nerves in Inflammatory Bowel Disease. PLoS ONE, 2013, 8, e64216.	1.1	37
43	MIR141 Expression Differentiates Hashimoto Thyroiditis from PTC and Benign Thyrocytes in Irish Archival Thyroid Tissues. Frontiers in Endocrinology, 2012, 3, 102.	1.5	20
44	MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma. Journal of Molecular Medicine, 2012, 90, 1449-1458.	1.7	93
45	Centrifugo-magnetophoretic particle separation. Microfluidics and Nanofluidics, 2012, 13, 899-908.	1.0	53
46	RET protein expression in papillary renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 900-905.	0.8	14
47	Epitope presentation is an important determinant of the utility of antigens identified from protein arrays in the development of autoantibody diagnostic assays. Journal of Proteomics, 2012, 75, 4668-4675.	1.2	18
48	Suppression of cancer stemness p21-regulating mRNA and microRNA signatures in recurrent ovarian cancer patient samples. Journal of Ovarian Research, 2012, 5, 2.	1.3	11
49	Low MAD2 expression levels associate with reduced progressionâ€free survival in patients with highâ€grade serous epithelial ovarian cancer. Journal of Pathology, 2012, 226, 746-755.	2.1	64
50	Inkjet-like printing of single-cells. Lab on A Chip, 2011, 11, 2447.	3.1	126
51	Platelet Adhesion and Degranulation Induce Pro-Survival and Pro-Angiogenic Signalling in Ovarian Cancer Cells. PLoS ONE, 2011, 6, e26125.	1.1	141
52	MYBL2 (B-MYB) in Cervical Cancer: Putative Biomarker. International Journal of Gynecological Cancer, 2011, 21, 206-212.	1.2	17
53	The role of secreted frizzled-related protein 2 expression in prostate cancer. Histopathology, 2011, 59, 1240-1248.	1.6	27
54	BRAFV600E: Implications for Carcinogenesis and Molecular Therapy. Molecular Cancer Therapeutics, 2011, 10, 385-394.	1.9	373

#	Article	IF	CITATIONS
55	Evaluation of Zinc-α-2-Glycoprotein and Proteasome Subunit β-Type 6 Expression in Prostate Cancer Using Tissue Microarray Technology. Applied Immunohistochemistry and Molecular Morphology, 2010, 18, 512-517.	0.6	8
56	All azoospermic males should be screened for cystic fibrosis mutations before intracytoplasmic sperm injection. Fertility and Sterility, 2010, 94, 2448-2450.	0.5	14
57	RET/PTC Rearrangement Occurring in Primary Peritoneal Carcinoma. International Journal of Surgical Pathology, 2009, 17, 187-197.	0.4	15
58	<i>FOXA1</i> Is a Potential Oncogene in Anaplastic Thyroid Carcinoma. Clinical Cancer Research, 2009, 15, 3680-3689.	3.2	75
59	Regulation of microRNA biosynthesis and expression in 2102Ep embryonal carcinoma stem cells is mirrored in ovarian serous adenocarcinoma patients. Journal of Ovarian Research, 2009, 2, 19.	1.3	20
60	Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma. Modern Pathology, 2009, 22, 197-205.	2.9	80
61	Gene Expression Profiling in Cervical Cancer: Identification of Novel Markers for Disease Diagnosis and Therapy. Methods in Molecular Biology, 2009, 511, 333-359.	0.4	42
62	Gene Expression Analysis of Diagnostic Biopsies Predicts Pathological Response to Neoadjuvant Chemoradiotherapy of Esophageal Cancer. Annals of Surgery, 2009, 250, 729-737.	2.1	71
63	miR-29b Expression Is Associated With Disease-Free Survival in Patients With Ovarian Serous Carcinoma. International Journal of Gynecological Cancer, 2009, 19, 641-647.	1.2	55
64	Improved RNA quality and TaqMan® Pre-amplification method (PreAmp) to enhance expression analysis from formalin fixed paraffin embedded (FFPE) materials. BMC Biotechnology, 2008, 8, 10.	1.7	66
65	Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. Modern Pathology, 2008, 21, 676-684.	2.9	91
66	Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Molecular Cancer, 2008, 7, 35.	7.9	269
67	ret/PTC-1 expression alters the immunoprofile of thyroid follicular cells. Molecular Cancer, 2008, 7, 44.	7.9	4
68	An integrative model for recurrence in ovarian cancer. Molecular Cancer, 2008, 7, 8.	7.9	30
69	Geographical mapping of a multifocal thyroid tumour using genetic alteration analysis & miRNA profiling. Molecular Cancer, 2008, 7, 89.	7.9	21
70	p16INK4A genetic and epigenetic profiles differ in relation to age and site in head and neck squamous cell carcinomas. Human Pathology, 2008, 39, 452-458.	1.1	69
71	Lack of Association between Measles Virus Vaccine and Autism with Enteropathy: A Case-Control Study. PLoS ONE, 2008, 3, e3140.	1.1	109
72	Low-Level TOP2A Amplification in Prostate Cancer Is Associated with HER2 Duplication, Androgen Resistance, and Decreased Survival. Cancer Research, 2007, 67, 2893-2898.	0.4	40

#	Article	IF	CITATIONS
73	BRAF T1799A Mutation Occurring in a Case of Malignant Struma Ovarii. International Journal of Surgical Pathology, 2007, 15, 116-120.	0.4	31
74	Effect of BRAFV600E mutation on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model. Molecular Cancer, 2007, 6, 21.	7.9	57
75	Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnology, 2007, 7, 36.	1.7	306
76	Free fetal DNA is not increased before 20 weeks in intrauterine growth restriction or pre-eclampsia. Prenatal Diagnosis, 2007, 27, 174-179.	1.1	47
77	A molecular expression signature distinguishing follicular lesions in thyroid carcinoma using preamplification RT-PCR in archival samples. Modern Pathology, 2007, 20, 1095-1102.	2.9	34
78	Heterogeneous expression of ?-methylacyl-CoA racemase in prostatic cancer correlates with Gleason score. Histopathology, 2007, 50, 243-251.	1.6	27
79	Expression microarray analysis of papillary thyroid carcinoma and benign thyroid tissue: emphasis on the follicular variant and potential markers of malignancy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 450, 249-260.	1.4	41
80	Low-Level Genomic Instability Is a Feature of Papillary Thyroid Carcinoma: An Array Comparative Genomic Hybridization Study of Laser Capture Microdissected Papillary Thyroid Carcinoma Tumors and Clonal Cell Lines. Archives of Pathology and Laboratory Medicine, 2007, 131, 65-73.	1.2	22
81	Effect of ret/PTC 1 rearrangement on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model. Molecular Cancer, 2006, 5, 70.	7.9	59
82	Future molecular aspects of cervical cytology. Current Diagnostic Pathology, 2006, 12, 104-113.	0.4	3
83	Squamous cell carcinoma of the head and neck in young Irish adults. British Journal of Oral and Maxillofacial Surgery, 2006, 44, 203-206.	0.4	33
84	Genome-wide analysis of deoxyribonucleic acid in endometrial cancer using comparative genomic hybridization microarrays. International Journal of Gynecological Cancer, 2006, 16, 834-842.	1.2	13
85	Distinct array comparative genomic hybridization profiles in oral squamous cell carcinoma occurring in young patients. Head and Neck, 2006, 28, 330-338.	0.9	35
86	Topoisomerase II-Â expression increases with increasing Gleason score and with hormone insensitivity in prostate carcinoma. Journal of Clinical Pathology, 2006, 59, 721-724.	1.0	25
87	Quantitation of CDC6 and MCM5 mRNA in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix. Modern Pathology, 2005, 18, 844-849.	2.9	43
88	Detection of a Tyrosine Phosphatase LAR on Intestinal Epithelial Cells and Intraepithelial Lymphocytes in the Human Duodenum. Mediators of Inflammation, 2005, 2005, 23-30.	1.4	3
89	Molecular pathology of prostate cancer. Journal of Clinical Pathology, 2005, 58, 673-684.	1.0	112
90	Analysis of DNA in Endometrial Cancer Cells Treated with Phyto-Estrogenic Compounds using Comparative Genomic Hybridisation Microarrays. Planta Medica, 2005, 71, 435-439.	0.7	11

#	Article	IF	CITATIONS
91	Molecular classification and biomarker discovery in papillary thyroid carcinoma. Expert Review of Molecular Diagnostics, 2005, 5, 927-946.	1.5	33
92	p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer. Journal of Clinical Pathology, 2005, 58, 525-534.	1.0	190
93	Oestrogen regulated gene expression in normal and malignant endometrial tissue. Maturitas, 2005, 51, 187-198.	1.0	18
94	Array comparative genomic hybridisation analysis of gamma-irradiated human thyrocytes. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 445, 396-404.	1.4	14
95	P16INK4A positivity in benign, premalignant and malignant cervical glandular lesions: a potential diagnostic problem. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 445, 610-615.	1.4	62
96	Nucleic acid microarrays: an overview. Current Diagnostic Pathology, 2003, 9, 155-158.	0.4	8
97	Quality-control issues for PCR-based assays in the molecular laboratory. Current Diagnostic Pathology, 2003, 9, 165-172.	0.4	2
98	p16INK4A as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrepTM smears. Journal of Clinical Pathology, 2003, 56, 56-63.	1.0	173
99	Ret/PTC Chimeric Transcripts in an Irish Cohort of Sporadic Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 938-941.	1.8	23
100	Real-Time Analysis of β- and γ-Catenin mRNA Expression in ret/PTC-1 Activated and Nonactivated Thyroid Tissues. Diagnostic Molecular Pathology, 2003, 12, 44-49.	2.1	4
101	RET/PTC Rearrangements in Hashimoto's Thyroiditis. International Journal of Surgical Pathology, 2002, 10, 167-168.	0.4	16
102	Potential viral pathogenic mechanism for new variant inflammatory bowel disease. Journal of Clinical Pathology, 2002, 55, 84-90.	2.1	138
103	Detection of measles virus in children with ileo-colonic lymphoid nodular hyperplasia, enterocolitis and developmental disorder. Molecular Psychiatry, 2002, 7, S47-S48.	4.1	23
104	Expression profile of human herpesvirus 8 (HHV-8) in pyothorax associated lymphoma and in effusion lymphoma. Journal of Clinical Pathology, 2001, 54, 80-85.	2.1	16
105	Improved in situ detection method for telomeric tandem repeats in metaphase spreads and interphase nuclei. Journal of Clinical Pathology, 2000, 53, 48-50.	2.1	12
106	Cellular localisation of HHV-8 in Castleman's disease: is there a link with lymph node vascularity?. Journal of Clinical Pathology, 2000, 53, 69-76.	2.1	24
107	Localisation of HHV-8 in AIDS related lymphadenopathy. Journal of Clinical Pathology, 2000, 53, 43-47.	2.1	9
108	Assessment ofret/PTC-1 rearrangements in neoplastic thyroid tissue using TaqMan RT-PCR. Journal of Pathology, 2000, 192, 32-36.	2.1	35

#	Article	IF	CITATIONS
109	TSH receptor status of thyroid neoplasms?TaqMan RT-PCR analysis of archival material. , 1999, 188, 87-92.		57
110	Irish association for cancer research. Irish Journal of Medical Science, 1994, 163, 341-354.	0.8	0
111	TaqMan® Technology and Real-Time Polymerase Chain Reaction. , 0, , 251-268.		5
112	The In-situ Polymerase Chain Reaction. , 0, , 233-250.		0